Meta-analysis strengthens commercial case for broader ERA indication expansion
A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of Nephrology, highlighted compelling evidence that endothelin receptor antagonists (ERAs) offer substantial therapeutic benefits for patients with chronic kidney disease (CKD) while clarifying their safety profile - particularly regarding fluid retention concerns.
The meta-analysis strengthens the commercial case for broader ERA indication expansion beyond immunoglobulin A (IgA) nephropathy into diabetic kidney disease, says intelligence and productivity platform GlobalData.
The analysis validates ERAs as disease-modifying agents in CKD, offering clinically relevant benefits that extend beyond symptomatic proteinuria reduction to meaningful hard endpoints like end-stage kidney disease (ESKD) prevention.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze